---
title: "18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard"
date: "2025-02-09 00:04:00"
summary: "The health sector had 21 companies reporting their quarterly earnings this week, with 18 of them beating profit estimates for the quarter. Quarter-To-Date, The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV) traded down 4% compared to the broader S&amp;P 500 sector’s 5.8% gain. The sector has seen a moderate..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

The health sector had 21 companies reporting their quarterly earnings this week, with 18 of them beating profit estimates for the quarter.

Quarter-To-Date, The Health Care Select Sector SPDR Fund ETF (NYSEARCA:[XLV](https://seekingalpha.com/symbol/XLV "The Health Care Select Sector SPDR® Fund ETF")) traded down 4% compared to the broader S&P 500 sector’s 5.8% gain.

The sector has seen a moderate stock movement in the quarter, and this week, it saw major pharmaceutical companies report their quarterly results.

Out of the 18 companies, 3 companies missed profit estimates while 18 were a beat. In terms of revenue, 4 companies missed revenue estimates while the rest beat estimates.

The following are the largest healthcare companies that reported earnings this week.

Pfizer ([PFE](https://seekingalpha.com/symbol/PFE "Pfizer Inc.")) on Tuesday [reaffirmed](https://seekingalpha.com/news/4402612-pfizer-2025-guidance-falls-short-expectations) its 2025 financial guidance, but the midpoints for revenue ($62.5B) and EPS ($2.90) were slightly below consensus estimates. The company beat Q4 expectations, with strong growth in primary care and oncology (both up 27% YoY).

Merck ([MRK](https://seekingalpha.com/symbol/MRK "Merck & Co., Inc.")) shares on Tuesday [dropped](https://seekingalpha.com/news/4402559-merck-stock-slides-as-2025-earnings-outlook-misses-estimates) after issuing a 2025 outlook below Wall Street estimates and announcing a temporary pause in Gardasil shipments to China from February through mid-year.

Bristol-Myers Squibb ([BMY](https://seekingalpha.com/symbol/BMY "Bristol-Myers Squibb Company")) on Thursday said it [beat](https://seekingalpha.com/news/4404333-bristol-myers-stock-slips-amid-outlook-concerns) Street forecasts with its Q4 2024 results, but its 2025 outlook fell short of analysts’ expectations.

Eli Lilly ([LLY](https://seekingalpha.com/symbol/LLY "Eli Lilly and Company")) on Thursday [reported](https://seekingalpha.com/news/4404294-eli-lilly-stock-rises-q4-2024-beat) its Q4 2024 results, exceeding Wall Street estimates and indicating a more than twofold rise in revenue from its weight loss and obesity drugs Mounjaro and Zepbound.

At industry level, 2 were biotechnology companies, 7 were health care equipment and supplies, 5 were health care provider and services, 3 were life science tools and services and 4 were pharmaceuticals.

[seekalpha](https://seekingalpha.com/news/4405247-18-out-of-21-healthcare-companies-beat-profit-estimates-this-week-earnings-scorecard)
